Gilead Sciences, Inc. vs Remitly Global Inc — how do they compare? Gilead Sciences, Inc. trades at $135.41 (market cap $168.35B), while Remitly Global Inc trades at $23.73 (market cap $4.97B). The key difference: Gilead Sciences, Inc. is far larger — about 33.9× Remitly Global Inc's market cap, and Gilead Sciences, Inc. pays a 2.42% dividend while Remitly Global Inc pays none. Which is the better fit depends on your goals.
| GILD | RELY | |
|---|---|---|
Market Cap | $168.35B | $4.97B |
Sector | Health | Technology |
52-Week High | $155.80 | $25.93 |
52-Week Low | $110.56 | $12.20 |
Enterprise Value | $191.42B | $4.33B |
Dividend Yield | 2.42% | — |
Trailing returns across standard periods
Latest headlines on both assets
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. Its revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
Read more on RELY →